Cargando…
The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
OBJECTIVE: To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. METHODS: Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970885/ https://www.ncbi.nlm.nih.gov/pubmed/35368892 http://dx.doi.org/10.1155/2022/2700166 |
_version_ | 1784679530411065344 |
---|---|
author | Wang, Zhixin Chen, Jiaqi Li, Qianyu Li, Na Yu, Jing Liu, Feng |
author_facet | Wang, Zhixin Chen, Jiaqi Li, Qianyu Li, Na Yu, Jing Liu, Feng |
author_sort | Wang, Zhixin |
collection | PubMed |
description | OBJECTIVE: To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. METHODS: Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to January 2020 were randomized to treatment with axitinib (control group, n = 27) or axitinib combined with tislelizumab (study group, n = 22). The clinical efficacy, renal function and adverse reactions were compared between the two groups. RESULTS: After treatment, both groups showed a significant decrease in blood urea nitrogen (BUN) and serum creatinine (SCR), but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). After treatment, both groups showed a significant decrease in TNF-β1, VEGF, TIMP-1, and MMP-2, but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). The study group had significantly higher rates of adverse reactions (p < 0.05). Significant difference was observed in ORR (59.1% vs 40.7%) and DCR (81.8% vs 66.7%) between the study group and the control group, with higher results in study group (p < 0.05). The study group was superior to the control group in OS (p < 0.05). CONCLUSION: Our study presents an effective alternative for advanced renal cell carcinoma by using axitinib plus tislelizumab. Limitations merit attention, and the study group had higher rates of adverse reactions. Therefore, further studies are suggested to secure a larger population of subjects. |
format | Online Article Text |
id | pubmed-8970885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-89708852022-04-01 The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma Wang, Zhixin Chen, Jiaqi Li, Qianyu Li, Na Yu, Jing Liu, Feng J Oncol Research Article OBJECTIVE: To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. METHODS: Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to January 2020 were randomized to treatment with axitinib (control group, n = 27) or axitinib combined with tislelizumab (study group, n = 22). The clinical efficacy, renal function and adverse reactions were compared between the two groups. RESULTS: After treatment, both groups showed a significant decrease in blood urea nitrogen (BUN) and serum creatinine (SCR), but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). After treatment, both groups showed a significant decrease in TNF-β1, VEGF, TIMP-1, and MMP-2, but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). The study group had significantly higher rates of adverse reactions (p < 0.05). Significant difference was observed in ORR (59.1% vs 40.7%) and DCR (81.8% vs 66.7%) between the study group and the control group, with higher results in study group (p < 0.05). The study group was superior to the control group in OS (p < 0.05). CONCLUSION: Our study presents an effective alternative for advanced renal cell carcinoma by using axitinib plus tislelizumab. Limitations merit attention, and the study group had higher rates of adverse reactions. Therefore, further studies are suggested to secure a larger population of subjects. Hindawi 2022-03-24 /pmc/articles/PMC8970885/ /pubmed/35368892 http://dx.doi.org/10.1155/2022/2700166 Text en Copyright © 2022 Zhixin Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wang, Zhixin Chen, Jiaqi Li, Qianyu Li, Na Yu, Jing Liu, Feng The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma |
title | The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma |
title_full | The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma |
title_fullStr | The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma |
title_full_unstemmed | The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma |
title_short | The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma |
title_sort | effects of axitinib plus tislelizumab in the treatment of advanced renal cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970885/ https://www.ncbi.nlm.nih.gov/pubmed/35368892 http://dx.doi.org/10.1155/2022/2700166 |
work_keys_str_mv | AT wangzhixin theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT chenjiaqi theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT liqianyu theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT lina theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT yujing theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT liufeng theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT wangzhixin effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT chenjiaqi effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT liqianyu effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT lina effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT yujing effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma AT liufeng effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma |